Achilles Therapeutics Q4 EPS $(0.46) May Not Be Comparable To $(0.14) Estimate, Cash Position Of $131.5M Supports Operations Through 2025
Achilles Therapeutics Q4 EPS $(0.46) May Not Be Comparable To $(0.14) Estimate, Cash Position Of $131.5M Supports Operations Through 2025
Achilles Therapeutics第四季度每股收益美元（0.46美元）可能無法與估計的0.14美元（0.14美元）相提並論，1.315億美元的現金狀況支持2025年之前的運營
Achilles Therapeutics (NASDAQ:ACHL) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.14) by 228.57 percent. This is a 24.59 percent increase over losses of $(0.61) per share from the same period last year.
Achilles Therapeutics（納斯達克股票代碼：ACHL）公佈的季度虧損爲每股0.46美元，比分析師普遍預期的0.14美元（0.14美元）低228.57％。與去年同期每股虧損0.61美元（0.61美元）相比，增長了24.59％。